Table 1 Patient characteristics of patients with DIP OA at cohort entry
Patient characteristics at baseline visit | csDMARD, n = 847 | bDMARD, n = 72 | Combination, n = 257 | Past-use, n = 19 | Never-use, n = 145 |
|---|---|---|---|---|---|
Mean age [years] (SD) | 60.1 (9.9) | 61.9 (10.5) | 58.6 (10.6) | 60.7 (9.9) | 60.9 (10.1) |
Female (%) | 653 (77.1%) | 60 (83.3%) | 195 (75.9%) | 13 (68.4%) | 112 (77.2%) |
Mean follow-up time [years] (SD) | 3.9 (2.3) | 3.4 (1.6) | 3.4 (1.9) | 2.8 (1.2) | 4.3 (2.8) |
Mean BMI (SD) | 25.9 (4.9) | 24.9 (4.0) | 25.6 (5.8) | 25.6 (2.3) | 25.6 (4.5) |
Missing (%) | 152 (17.9%) | 3 (4.2%) | 9 (3.4%) | 6 (31.6%) | 58 (40.0%) |
Median RA duration [years] (IQR) | 5.3 (2.0–12.8) | 11.2 (5.0–18.9) | 8.0 (3.9–14.4) | 6.5 (2.7–8.7) | 6.9 (1.7–16.4) |
Missing (%) | 21 (2.5%) | 3 (4.2%) | 8 (3.0%) | 1 (5.3%) | 7 (4.8%) |
RF negative (%) | 275 (32.5%) | 33 (45.8%) | 77 (30.0%) | 6 (31.6%) | 53 (36.6%) |
RF positive (%) | 559 (66.0%) | 36 (50.0%) | 163 (63.4%) | 10 (52.6%) | 78 (53.8%) |
Missing (%) | 13 (1.5%) | 3 (4.2%) | 17 (6.6%) | 3 (15.8%) | 14 (9.7%) |
Mean DAS28-esra (SD) | 4.0 (1.5) | 4.1 (1.3) | 3.9 (1.5) | 3.7 (1.8) | 4.4 (1.4) |
Missing (%) | 44 (5.2%) | 1 (1.4%) | 13 (5.1%) | 4 (21.1%) | 37 (25.6%) |
≥ 365 days of current csDMARD useb (%) | 281 (33.2%) | 0 | 129 (50.2%) | 0 | 0 |
≥ 365 days of current bDMARD usec (%) | 0 | 18 (25.0%) | 56 (21.8%) | 0 | 0 |
Prednisone used (%) | 443 (52.3%) | 37 (51.4%) | 147 (57.2%) | 10 (52.6%) | 62 (42.8%) |
Cardiac disorderse (%) | 80 (9.5%) | 12 (16.7%) | 25 (9.7%) | 7 (36.8%) | 10 (6.9%) |
Hypertensionf (%) | 206 (24.3%) | 27 (37.5%) | 52 (20.2%) | 4 (21.1%) | 37 (25.5%) |
Osteoporosis or fractureg (%) | 106 (12.5%) | 27 (37.5%) | 76 (29.6%) | 1 (5.3%) | 16 (11.0%) |
Large joint osteoarthritish (%) | 82 (9.7%) | 9 (12.5%) | 45 (17.5%) | 5 (26.3%) | 17 (11.7%) |
Hand surgery (%) | 67 (7.9%) | 15 (20.8%) | 33 (12.8%) | 1 (5.3%) | 12 (8.3%) |